AbbVie
ABBV
#26
Rank
NZ$691.65 B
Marketcap
NZ$391.34
Share price
-1.15%
Change (1 day)
34.26%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) Fails to deliver data

Key failure to deliver metrics for AbbVie:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for AbbVie (ABBV) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for AbbVie (ABBV) - since 2013

Volume in USD (price x number of shares), data since 2013

AbbVie (ABBV) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2025NZ$70.24 M-64.39%
2024NZ$0.19 B-13.93%
2023NZ$0.22 B-63.52%
2022NZ$0.62 B629.28%
2021NZ$86.13 M-77.97%
2020NZ$0.39 B85.64%
2019NZ$0.21 B-52.97%
2018NZ$0.44 B269.88%
2017NZ$0.12 B-48.45%
2016NZ$0.23 B-37.53%
2015NZ$0.37 B-44.13%
2014NZ$0.67 B2387.79%
2013NZ$27.05 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
Pfizer
PFE
NZ$24.63 MNZ$0.10 B๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.09 MNZ$0.21 B๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$0.21 BNZ$0.37 B๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$5.75 MNZ$0.21 B๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$60.15 MNZ$0.26 B๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$22.86 MNZ$94.5 M๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$72.01 MNZ$0.40 B๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$21.14 MNZ$0.11 B๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$2.71 MNZ$30.9 M๐Ÿ‡บ๐Ÿ‡ธ USA